查詢結果分析
來源資料
相關文獻
- Deeper and Early Molecular Response Is a Good Predictor for Risk of Relapse in Patients with Acute Promyelocytic Leukemia
- Rharmacological Prevention of Relapse
- 上頜掀開術切除局部復發之鼻咽癌--三例報告
- Prolonged Survival of Patient with Recurrent Pulmonary Metastasis from a Primary Adrenal Cortical Carcinoma--A Case Report
- Neurobiology of Recurrent Affective Illness
- 海洛英成癮者情緒低落之相關因素
- 減少腹腔鏡治療癌症病患後穿刺孔復發的方法
- Recurrent Herpetic Keratitis Induced by Laser Iridectomy: Case Report
- Relapsing Polychondritis: A Case Report
- 復發性多軟骨炎
頁籤選單縮合
題 名 | Deeper and Early Molecular Response Is a Good Predictor for Risk of Relapse in Patients with Acute Promyelocytic Leukemia=治療初期較深的分子生物反應在急性前骨髓性白血病病人的治療上是好的預測因子 |
---|---|
作 者 | 廖浚凱; 郭景元; 裴松南; 馬銘君; 施麗雲; 王銘崇; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 2:2 2015.06[民104.06] |
頁 次 | 頁132-138 |
分類號 | 415.635 |
關鍵詞 | 急性前骨髓性白血病; 復發; Acute prolmyelocytic leukemia; PML-RARα; Relapse; |
語 文 | 英文(English) |
中文摘要 | 背景:急性前骨髓性白血病(APL)在現今結合全反式 A 酸及 Anthracycline 類藥物的治療 下,已有不錯的成績。但仍有部分病人產生復發進而導致死亡,本研究回顧近 10 年在本 院治療的 APL 病人,分析診斷時的各項因子(年齡、性別、白血球數等)並追蹤治療過程 中 PML-RARα 融合基因量的變化,分析其與預後之關係。 方法&結果:共 33 位病人於本院治療,其中 29 位達到血液完全緩解,24 位達完全分子 生物學緩解。平均存活時間為 92.8 月。不良預後因子分別為診斷時高的白血球數(P=0.015) 及復發(P=0.003)。8 位病人復發,無復發存活期為 41.8 個月。誘導治療後 PML-RARα 轉 錄值下降大於 4.0log 或測不到為一好的預後因子(P=0.028)。 結論:復發在 APL 預後上至為關鍵,而誘導治療後較深的分子生物學反應意味著較少的 復發,因此可視為一個好的預測因子。 |
英文摘要 | Background: Conventional treatment of acute promyelocytic leukemia (APL) including all-trans retinoic acid (ATRA) with anthracycline had led to good patient response and survival. However, instances of relapse continue to occur, and remain the major problem with this course of treatment. Patients and Methods: We collected the data of patients with newly diagnosed APL for the period 2004 to 2014, retrospectively. Data analysis included age, sex, initial white blood cell (WBC) count, coagulopathy and PML-RARα subtype. We also correlated PML-RARα fusion transcript level during treatment with outcome. Results: A total of 33 patients were ultimately included in this study. Twenty-nine patients achieved complete hematologic remission(CHR) and 24 patients achieved complete molecular remission(CMR). The median overall survival duration was 92.8 months. Patient relapse and initially high WBC count were 2 factors associated with poor survival (P = 0.003; P = 0.015). Eight patients relapsed and the relapse-free survival (RFS) was 41.8 months. A reduction exceeding 4 log of PML-RARα transcript level after induction and undetectable PML-RARα transcript after treatment was associated with better RFS (P = 0.028). Conclusions: Deeper molecular response after induction therapy was associated with a reduction in relapse and could be used to predict risk of relapse in newly diagnosed patient under conventional treatment. |
本系統中英文摘要資訊取自各篇刊載內容。